US Pharma MarketingZealand inks up to $1.3B deal for AI-designed obesity treatments
Zealand Pharma pays $30M upfront in a deal worth up to $1.3B to design obesity proteins with Generate’s AI platform. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Zealand Pharma said Tuesday it will develop new protein-based treatments for obesity and other metabolic diseases with the help of Generate Biomedicines’ AI technology.
The Danish drugmaker is spending $30 million upfront for two initial ...
Source: Endpoints News